Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

Blood

Volumn 128, Issue 21, 2016, Pages 2489-2496

  Cheson, Bruce D ^a   Ansell, Stephen ^b   Schwartz, Larry ^c   Gordon, Leo I ^d   Advani, Ranjana ^e   Jacene, Heather A ^f   Hoos, Axel ^g   Barrington, Sally F ^h   Armand, Philippe ^f  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e STANFORD UNIVERSITY   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g GLAXOSMITHKLINE   (United States)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOLOGIC FACTOR;

ARTICLE; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; FOLLOW UP; HUMAN; LYMPHOMA; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; CLASSIFICATION; IMMUNOTHERAPY; PROCEDURES;

HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LYMPHOMA;

EID: 85009857896     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-05-718528     Document Type: Article

References (39)

1. Cheson BD, Horning SJ, Coiffier B, et al; NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non- Hodgkin's lymphomas. J Clin Oncol. 1999; 17(4):1244-1253.
2. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5): 579-586.
3. Cheson BD, Fisher RI, Barrington SF, et al; Alliance, Australasian Leukaemia and Lymphoma Group Eastern Cooperative Oncology Group European Mantle Cell Lymphoma Consortium Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/ Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea German High-Grade Lymphoma Study Group German Hodgkin's Study Group Japanese Lymphorra Study Group Lymphoma Study Association; NCIC Clinical Trials Group Nordic Lymphoma Study Group Southwest Oncology Group United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
4. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24(34): 5343-5349.
5. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008; 111(11):5291-5297.
6. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29): 3688-3695.
7. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622-1627.
8. Eve HE, Rule SA. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma. Br J Haematol. 2010;151(4):410-412.
9. Corazzelli G, De Filippi R, Capobianco G, et al. Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. Am J Hematol. 2010;85(1): 87-90.
10. Chanan-Khan AA, Chitta K, Ersing N, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011; 155(4):457-467.
11. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
12. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
13. Han HS, Escalón MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20(2):309-318.
14. Skoura E, Ardeshna K, Halsey R, Wan S, Kayani I. False-positive 18F-FDG PET/CT imaging: dramatic "Flare Response" after rituximab administration. Clin Nucl Med. 2016;41(3): e171-e172.
15. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004;15(10): 1481-1483.
16. Ghobrial IM, Fonseca R, Greipp PR, et al; Eastern Cooperative Oncology Group. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101(11): 2593-2598.
17. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
18. Byrd JC, Brown JR, O'Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
19. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
20. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
21. Wodarz D, Garg N, Komarova NL, et al. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014; 123(26):4132-4135.
22. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390-3397.
23. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012; 119(5):1182-1189.
24. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12): 1810-1817.
25. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(23):2820-2822.
26. Scahadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilumumab in unresectable or metastatic melanoma. J Clin Oncol. 2015; 33(17):1889-1894.
27. Robert C, Ribas A, Wolchok JD, et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948): 1109-1117.
28. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or montherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
29. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti- CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384.
30. Hoos A, Wolchok JD, Humphrey RW, Hodi FS. Immune-realted response criteria - capturing clinical activity in immuno-oncology. Clin Cancer Res. 2015;21:4989-4991.
31. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23): 7412-7420.
32. Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune-realted response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13): 1510-1517.
33. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4): 311-319.
34. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014; 15(1):69-77.
35. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23): 2698-2674.
36. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. The role of imaging in the staging and response assessment of lymphoma: consensus of the ICML Imaging Working Group. J Clin Oncol. 2014;32: 3048-3058.
37. Oxnard GR, Zhao B, Sima CS, et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol. 2011;29(23):3114-3119.
38. Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679-3687.
39. Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541-549.